C

Canbridge Pharmaceuticals Inc
HKEX:1228

Watchlist Manager
Canbridge Pharmaceuticals Inc
HKEX:1228
Watchlist
Price: 2.52 HKD 16.13%
Market Cap: 1.3B HKD

Intrinsic Value

1228 price has not been updated for more than 11 months. This may indicate that the stock has been delisted.

The intrinsic value of one Canbridge Pharmaceuticals Inc stock under the Base Case scenario is 0.76 HKD. Compared to the current market price of 2.52 HKD, Canbridge Pharmaceuticals Inc is Overvalued by 70%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
0.76 HKD
Overvaluation 70%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation History
Canbridge Pharmaceuticals Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about Canbridge Pharmaceuticals Inc?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Canbridge Pharmaceuticals Inc valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Canbridge Pharmaceuticals Inc.

Explain Valuation
Compare Canbridge Pharmaceuticals Inc to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about Canbridge Pharmaceuticals Inc?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Canbridge Pharmaceuticals Inc

Current Assets 43.5m
Cash & Short-Term Investments 2m
Receivables 7.2m
Other Current Assets 34.4m
Non-Current Assets 62m
PP&E 730k
Intangibles 61.3m
Current Liabilities 506.2m
Accounts Payable 393m
Other Current Liabilities 113.2m
Non-Current Liabilities 8.4m
Long-Term Debt 8.4m
Efficiency

Free Cash Flow Analysis
Canbridge Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Canbridge Pharmaceuticals Inc

Revenue
62.6m CNY
Cost of Revenue
-22.3m CNY
Gross Profit
40.3m CNY
Operating Expenses
-186.4m CNY
Operating Income
-146.1m CNY
Other Expenses
10m CNY
Net Income
-136.1m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

Canbridge Pharmaceuticals Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROIC
ROIC is Increasing
Exceptional ROE
52/100
Profitability
Score

Canbridge Pharmaceuticals Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Canbridge Pharmaceuticals Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Long-Term Solvency
Short-Term Solvency
18/100
Solvency
Score

Canbridge Pharmaceuticals Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Canbridge Pharmaceuticals Inc

There are no price targets for Canbridge Pharmaceuticals Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Canbridge Pharmaceuticals Inc is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one Canbridge Pharmaceuticals Inc stock?

The intrinsic value of one Canbridge Pharmaceuticals Inc stock under the Base Case scenario is 0.76 HKD.

Is Canbridge Pharmaceuticals Inc stock undervalued or overvalued?

Compared to the current market price of 2.52 HKD, Canbridge Pharmaceuticals Inc is Overvalued by 70%.

Back to Top